IL161181A0 - Therapeutically useful triethyleneglycol cholesteryl oligonucleotides - Google Patents
Therapeutically useful triethyleneglycol cholesteryl oligonucleotidesInfo
- Publication number
- IL161181A0 IL161181A0 IL16118102A IL16118102A IL161181A0 IL 161181 A0 IL161181 A0 IL 161181A0 IL 16118102 A IL16118102 A IL 16118102A IL 16118102 A IL16118102 A IL 16118102A IL 161181 A0 IL161181 A0 IL 161181A0
- Authority
- IL
- Israel
- Prior art keywords
- seq
- induction
- composition
- triethyleneglycol
- therapeutically useful
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000006698 induction Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000011727 Caspases Human genes 0.000 abstract 1
- 108010076667 Caspases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000025084 cell cycle arrest Effects 0.000 abstract 1
- 230000008619 cell matrix interaction Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000006882 induction of apoptosis Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 210000002437 synoviocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32688401P | 2001-10-03 | 2001-10-03 | |
| PCT/IB2002/004065 WO2003028764A1 (en) | 2001-10-03 | 2002-10-03 | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161181A0 true IL161181A0 (en) | 2004-08-31 |
Family
ID=23274136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16118102A IL161181A0 (en) | 2001-10-03 | 2002-10-03 | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
| IL161181A IL161181A (en) | 2001-10-03 | 2004-03-30 | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL161181A IL161181A (en) | 2001-10-03 | 2004-03-30 | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7635686B2 (enExample) |
| EP (1) | EP1432450B1 (enExample) |
| JP (1) | JP4405259B2 (enExample) |
| KR (1) | KR100971571B1 (enExample) |
| CN (1) | CN100352510C (enExample) |
| AT (1) | ATE314096T1 (enExample) |
| AU (1) | AU2002341264B2 (enExample) |
| CA (1) | CA2462425A1 (enExample) |
| DE (1) | DE60208400T2 (enExample) |
| DK (1) | DK1432450T3 (enExample) |
| ES (1) | ES2250713T3 (enExample) |
| IL (2) | IL161181A0 (enExample) |
| MX (1) | MXPA04002530A (enExample) |
| PT (1) | PT1432450E (enExample) |
| WO (1) | WO2003028764A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60036019T2 (de) * | 1999-12-13 | 2008-05-29 | Bioniche Life Sciences Inc., Belleville | Synthetische oligonukleotide die therapeutisch nützlich sind |
| US7491805B2 (en) * | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| CN101160399A (zh) * | 2002-04-22 | 2008-04-09 | 拜奥尼茨生命科学公司 | 寡核苷酸组合物及其在调节免疫应答中的应用 |
| GB2443591B (en) * | 2005-09-07 | 2010-04-28 | Secr Defence | Adjuvanted vaccine |
| US20090054366A1 (en) * | 2007-06-15 | 2009-02-26 | Reliance Life Sciences Pvt. Ltd. | RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY |
| GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| DE69434614T2 (de) * | 1993-11-30 | 2006-10-05 | Tanox, Inc., Houston | Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung |
| US5756668A (en) * | 1994-11-15 | 1998-05-26 | The Johns Hopkins University School Of Medicine | Hypermethylated in cancer polypeptide, HIC-1 |
| US5643890A (en) | 1995-01-31 | 1997-07-01 | The Board Of Regents Of The University Of Nebraska | Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases |
| WO1997014440A1 (en) | 1995-10-19 | 1997-04-24 | Johnson & Johnson Interventional Systems | Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia |
| US5958780A (en) * | 1997-06-30 | 1999-09-28 | Boston Advanced Technologies, Inc. | Method for marking and identifying liquids |
| AU9220498A (en) | 1997-09-04 | 1999-03-22 | Bayer Corporation | Oligonucleotide probes bearing quenchable fluorescent labels, and methods of usethereof |
| EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| DE60036019T2 (de) * | 1999-12-13 | 2008-05-29 | Bioniche Life Sciences Inc., Belleville | Synthetische oligonukleotide die therapeutisch nützlich sind |
| US7087586B2 (en) * | 2001-04-24 | 2006-08-08 | Bioniche Life Sciences, Inc. | Oligonucleotide compositions and their use to induce differentiation of cells |
| WO2002092006A2 (en) * | 2001-05-16 | 2002-11-21 | Micrologix Biotech, Inc. | Nucleic acid-based compounds and methods of use thereof |
-
2002
- 2002-10-03 IL IL16118102A patent/IL161181A0/xx unknown
- 2002-10-03 CN CNB028241916A patent/CN100352510C/zh not_active Expired - Fee Related
- 2002-10-03 PT PT02775055T patent/PT1432450E/pt unknown
- 2002-10-03 DE DE60208400T patent/DE60208400T2/de not_active Expired - Lifetime
- 2002-10-03 ES ES02775055T patent/ES2250713T3/es not_active Expired - Lifetime
- 2002-10-03 JP JP2003532094A patent/JP4405259B2/ja not_active Expired - Fee Related
- 2002-10-03 US US10/264,280 patent/US7635686B2/en not_active Expired - Fee Related
- 2002-10-03 DK DK02775055T patent/DK1432450T3/da active
- 2002-10-03 AT AT02775055T patent/ATE314096T1/de active
- 2002-10-03 WO PCT/IB2002/004065 patent/WO2003028764A1/en not_active Ceased
- 2002-10-03 EP EP02775055A patent/EP1432450B1/en not_active Expired - Lifetime
- 2002-10-03 MX MXPA04002530A patent/MXPA04002530A/es active IP Right Grant
- 2002-10-03 AU AU2002341264A patent/AU2002341264B2/en not_active Ceased
- 2002-10-03 CA CA002462425A patent/CA2462425A1/en not_active Abandoned
- 2002-10-03 KR KR1020047004837A patent/KR100971571B1/ko not_active Expired - Fee Related
-
2004
- 2004-03-30 IL IL161181A patent/IL161181A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2250713T3 (es) | 2006-04-16 |
| WO2003028764A1 (en) | 2003-04-10 |
| DE60208400T2 (de) | 2006-07-06 |
| AU2002341264B2 (en) | 2007-07-12 |
| KR20040068114A (ko) | 2004-07-30 |
| CA2462425A1 (en) | 2003-04-10 |
| EP1432450B1 (en) | 2005-12-28 |
| CN100352510C (zh) | 2007-12-05 |
| DK1432450T3 (da) | 2006-05-15 |
| CN1599627A (zh) | 2005-03-23 |
| JP4405259B2 (ja) | 2010-01-27 |
| JP2005509607A (ja) | 2005-04-14 |
| PT1432450E (pt) | 2006-05-31 |
| EP1432450A1 (en) | 2004-06-30 |
| KR100971571B1 (ko) | 2010-07-20 |
| IL161181A (en) | 2010-06-30 |
| DE60208400D1 (de) | 2006-02-02 |
| US7635686B2 (en) | 2009-12-22 |
| ATE314096T1 (de) | 2006-01-15 |
| US20030125290A1 (en) | 2003-07-03 |
| HK1067308A1 (en) | 2005-04-08 |
| MXPA04002530A (es) | 2004-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE312202T1 (de) | Menschliche rnase h und entsprechende oligonukleotidverbindungen | |
| WO2002028904A3 (en) | Human anti-cd40 antibodies | |
| GB2340121B (en) | Delivery system | |
| HU9501963D0 (en) | 7-deazapurine modified oligonucleotides | |
| NZ335992A (en) | Substituted pyrimidinone and pyridone compounds and methods of use | |
| SG47918A1 (en) | Chloropyrimidine intermediates | |
| MX9804009A (es) | Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8. | |
| EP1325019A4 (en) | ANTISENSE MODULATION OF CLUSTERINEXPRESSION | |
| WO2003048315A3 (en) | Antisense modulation of mdm2 expression | |
| AU8490901A (en) | Urea compounds and methods of uses | |
| BR9811956A (pt) | Naftiridinonas para a inibição de proteìna tirosina cinase e de proliferação celular mediada por cinase de ciclo de célula | |
| IL147271A (en) | Isolated peptide ligands that bind to her2 | |
| BR0314099A (pt) | Polìmeros catiÈnicos disparáveis por ìons melhorados, método de feitura dos mesmos e itens usando os mesmos | |
| DK1123414T3 (da) | Antisense-modulering af integrin alpha 4.ekspression | |
| BR0008788A (pt) | Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase | |
| BG108180A (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| PT1432450E (pt) | Trietilenoglicol-colesteril-oligonucleotidos terapeuticamente uteis | |
| UY26426A1 (es) | Nuevos compuestos | |
| BR9912279A (pt) | Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas | |
| IL160408A0 (en) | Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides | |
| MY120530A (en) | Combination preparation for use in dementia | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| IL131478A0 (en) | Methods for treatment of scar tissue | |
| JP2005509607A5 (enExample) | ||
| AU5868699A (en) | Novel therapeutic use of compounds with beta-3-agonist activity |